Joseph Michael Fitzgerald - 03 Nov 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Issuer symbol
BSX
Transactions as of
03 Nov 2025
Net transactions value
-$3,665,838
Form type
4
Filing time
04 Nov 2025, 16:15:59 UTC
Previous filing
01 Oct 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fitzgerald Joseph Michael EVP & Group Pres, Cardiology 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH /s/ Susan Thompson, Attorney-in-Fact 04 Nov 2025 0001484186

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $1,307,500 +50,000 +28% $26.15 228,342 03 Nov 2025 Direct F1
transaction BSX Common Stock Sale $362,693 -3,600 -1.6% $100.75 224,742 03 Nov 2025 Direct F1, F2
transaction BSX Common Stock Sale $1,688,749 -16,928 -7.5% $99.76 207,814 03 Nov 2025 Direct F1, F3
transaction BSX Common Stock Sale $2,921,895 -29,472 -14% $99.14 178,342 03 Nov 2025 Direct F1, F4
holding BSX Common Stock 5,234 03 Nov 2025 By Child F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -50,000 -100% $0.000000 0 03 Nov 2025 Common Stock 50,000 $26.15 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.72 to $100.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.59 to $100.53, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F6 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.